Here are four updates from GI companies and practices over the past week:
GI & Endoscopy
New York University Langone Health opened a new, comprehensive IBD center for adults with Crohn's disease and ulcerative colitis, according to a Dec. 22 news release.
Private equity investment in the gastroenterology space has recovered from COVID-19-related delays and is on fire to end 2020. So, what's in store for 2021?
The Removing Barriers to Colorectal Cancer Screening Act of 2020 passed the U.S. House Dec. 9 and was included in the COVID-19 relief bill the Senate cleared Dec. 21.
COVID-19 disrupted private equity investment in the gastroenterology space but as the year comes to a close, practices are flocking to PE money establishing new platforms and growing established platforms.
Dallas-based GI Alliance expanded its Louisiana presence Dec. 17 through the acquisition of Metropolitan Gastroenterology Associates.
Dallas-based GI Alliance partnered with Gastrointestinal Associates in Jackson, Miss., expanding its presence into an eighth state, the platform announced Dec. 17.
Gastroenterologist compensation will be affected by COVID-19, ending a generally upward trend from the last several years.
Here are the most-read GI articles from Dec. 14-18:
The FDA accepted Takeda's new drug application for TAK-721, its eosinophilic esophagitis treatment, the company announced Dec. 15.
